Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01380756 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01380756 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 35 participants.
The verdict
NCT01380756, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The dose escalation part of the study is aimed at evaluating the safety, tolerability and PK (pharmacokinetics) of oral AMG 900 in subjects with acute myeloid leukemia. Up to 93 subjects may be enrolled in dose escalation. The dose expansion part of the study will consist of 20 subjects with acute myeloid leukemia. The dose of AMG 900 will be dependent upon data from the dose escalation part of the study.
Interventions
- DRUG Arm 1- Dose Escalation
- DRUG Arm 2- Dose Expansion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-10-04 |
| Est. Completion | 2014-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01380756
The ClinicalTrials.gov registry entry for NCT01380756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm 1- Dose Escalation is the first listed.
NCT01380756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01380756 about?
NCT01380756 is a clinical study titled "Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia". This study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The dose escalation part of the study is aimed at evaluating the safety, tolerability and PK (pharmacokinetics) of oral AMG 900 in subjects with acute myeloid leukemia. Up to 93 subjects may be enrolled in dose...
What is the current status of trial NCT01380756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-10-04. Estimated completion is 2014-09-04.
What interventions are being tested in trial NCT01380756?
The interventions under investigation include: Arm 1- Dose Escalation (DRUG), Arm 2- Dose Expansion (DRUG).
Who is sponsoring clinical trial NCT01380756?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.